Bev 2.0.

Biosimilars are a crucial avenue to combating the unwieldy power of Big Pharma in the era of targeted therapies. This trial aims to take down none other than bevacizumab itself from the throne of market exclusivity. This multi-national study enrolled 142 patients with metastatic colorectal cancer receiving first-line physician’s choice FOLFOX or FOLFIRI and randomized them to the addition of standard bevacizumab versus its biosimilar BEVZ92. The primary endpoint of bioequivalence (aka pharmacokinetics) was met, with impressive secondary endpoints (of pharmacodynamics) such as a median progression-free survival of 11 months in each arm. TBL: Be on the lookout for a more affordable bev-alternative for your patients, hopefully marketed under a catchier name than BEVZ92. | Romera, Lancet Gastroenterol Hepatol 2018